These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 19179222)

  • 1. Vaccine immunogenicity in injecting drug users.
    Schmidt M
    Lancet Infect Dis; 2009 Feb; 9(2):77-8. PubMed ID: 19179222
    [No Abstract]   [Full Text] [Related]  

  • 2. Vaccine immunogenicity in injecting drug users.
    Lugoboni F; Mezzelani P; Quaglio G
    Lancet Infect Dis; 2009 Nov; 9(11):652. PubMed ID: 19850220
    [No Abstract]   [Full Text] [Related]  

  • 3. Hepatitis B vaccination and injecting drug use: narrowing the efficacy-effectiveness gap.
    Maher L
    Int J Drug Policy; 2008 Dec; 19(6):425-8. PubMed ID: 18289840
    [No Abstract]   [Full Text] [Related]  

  • 4. Hepatitis B vaccination in prison with a 3-week schedule is more efficient than the standard 6-month schedule.
    Christensen PB; Fisker N; Krarup HB; Liebert E; Jaroslavtsev N; Christensen K; Georgsen J
    Vaccine; 2004 Sep; 22(29-30):3897-901. PubMed ID: 15364437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B vaccination and injecting drug users.
    Budd J; Robertson R; Elton R
    Br J Gen Pract; 2004 Jun; 54(503):444-7. PubMed ID: 15186567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B vaccine uptake among injecting drug users.
    Lawson J; Holtby I; Eynon C
    J Public Health (Oxf); 2004 Mar; 26(1):116-7. PubMed ID: 15044587
    [No Abstract]   [Full Text] [Related]  

  • 7. Isolated presence of antibody to hepatitis B core antigen in injection drug users: do they need to be vaccinated?
    Quaglio G; Lugoboni F; Vento S; Lechi A; Accordini A; Bossi C; Faccini M; Mecenero V; Pani A; Pantalena M; Residori M; Mezzelani P
    Clin Infect Dis; 2001 May; 32(10):E143-4. PubMed ID: 11317267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of perceptions of hepatitis B and C status. Injecting drug users need vaccination against hepatitis B.
    Ramsay ME; Balogun MA; Teo CG; Mortimer PP
    BMJ; 2000 Feb; 320(7233):512; author reply 513. PubMed ID: 10678875
    [No Abstract]   [Full Text] [Related]  

  • 9. Decline in hepatitis B infection observed after 11 years of regional vaccination among Danish drug users.
    Mössner BK; Skamling M; Jørgensen TR; Georgsen J; Pedersen C; Christensen PB
    J Med Virol; 2010 Oct; 82(10):1635-9. PubMed ID: 20827758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful use of Fendrix in HIV-infected non-responders to standard hepatitis B vaccines.
    de Silva TI; Green ST; Cole J; Stone BJ; Dockrell DH; Vedio AB
    J Infect; 2014 Apr; 68(4):397-9. PubMed ID: 24384506
    [No Abstract]   [Full Text] [Related]  

  • 11. No seroconversion after hepatitis B immunization.
    Cherian T; John TJ
    Indian Pediatr; 1997 Jun; 34(6):555-6. PubMed ID: 9357216
    [No Abstract]   [Full Text] [Related]  

  • 12. A boost to hepatitis B vaccine: no need for boosters.
    Aggarwal R
    Natl Med J India; 2005; 18(6):313-4. PubMed ID: 16483032
    [No Abstract]   [Full Text] [Related]  

  • 13. Gender differences in hepatitis C seroprevalence and suboptimal vaccination and hepatology services uptake amongst substance misusers.
    Marufu M; Williams H; Hill SL; Tibble J; Verma S
    J Med Virol; 2012 Nov; 84(11):1737-43. PubMed ID: 22997076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B vaccination.
    Gray J; Hewett N; Hiley A
    Br J Gen Pract; 2004 Sep; 54(506):704. PubMed ID: 15353063
    [No Abstract]   [Full Text] [Related]  

  • 15. Loss of antibodies, but not of protection.
    Wenzel JJ; Jilg W
    Lancet Infect Dis; 2010 Nov; 10(11):738-9. PubMed ID: 21029981
    [No Abstract]   [Full Text] [Related]  

  • 16. Changing serological status and low vaccination-induced protection rates against hepatitis B characterize chronic hepatitis C virus-infected injecting drug users in Greece: need for immunization policy.
    Elefsiniotis IS; Pantazis KD; Ketikoglou ID; Koutsounas SI; Tsianos EV
    Eur J Gastroenterol Hepatol; 2006 Nov; 18(11):1227-31. PubMed ID: 17033445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mathematical model of the antibody response to hepatitis B vaccines: implications for reduced schedules.
    Wilson JN; Nokes DJ; Medley GF; Shouval D
    Vaccine; 2007 May; 25(18):3705-12. PubMed ID: 17306427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody response to hepatitis B vaccination in urban, homeless adults.
    Jones T; Nyamathi A; Giger JN; Jacobsen SJ
    J Natl Black Nurses Assoc; 2007 Jul; 18(1):1-7. PubMed ID: 17679408
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatitis vaccination among drug users.
    Quaglio G; Lugoboni F; Mezzelani P; Des Jarlais DC; Lechi A
    Vaccine; 2006 Apr; 24(15):2702-9. PubMed ID: 16436307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of seroconversion after hepatitis B virus immunization.
    Diamond C
    Am J Public Health; 2004 Mar; 94(3):358; author reply 358-9. PubMed ID: 14998792
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.